Controlled-Release CNP Agonist for Achondroplasia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CNP therapies for achondroplasia face challenges due to the short half-life of CNP-22, requiring continuous infusion and extensive inactivation in subcutaneous tissue, leading to cardiovascular side effects such as hypotension, making it difficult to achieve efficacious levels without adverse effects.
Innovation Solution
A controlled-release CNP agonist with a release half-life of at least 6 hours and an EC50 at least 20-fold higher than the corresponding free CNP agonist, allowing for a higher, more efficacious dose with reduced cardiovascular side effects through reversible inactivation and continuous release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If continuous infusion of CNP is used to maintain efficacious levels, then therapeutic effect is improved, but treatment complexity and patient burden increase
Solution Approach 1:
The invention segments the continuous therapeutic effect into discrete controlled-release formulations (implants, injectables, or oral formulations) that release CNP agonist over extended periods (at least 6 hours half-life), eliminating the need for continuous infusion while maintaining reliable therapeutic levels through sustained release kinetics
Solution Approach 2:
The controlled-release formulations are prepared in advance with pre-loaded CNP agonist reservoirs or conjugates designed for sustained release, allowing administration as a single dose or intermittent doses rather than requiring continuous infusion setup and maintenance
2Reliability
If higher doses of CNP are administered to achieve efficacious levels, then therapeutic effect is improved, but cardiovascular side effects worsen
Solution Approach 1:
The invention employs dynamic controlled-release kinetics where CNP agonist is released at regulated rates over time (half-life at least 6 hours), creating a sustained but moderated concentration profile that maintains therapeutic efficacy while avoiding the sharp peaks associated with high bolus doses that cause cardiovascular side effects
Solution Approach 2:
The invention changes the pharmacokinetic parameters of CNP administration by using formulations with extended release half-lives and modified EC50 characteristics (at least 20-fold higher than free CNP agonist), transforming the dose-concentration-time profile to achieve therapeutic effects at lower peak concentrations that avoid cardiovascular toxicity
3Reliability
If CNP is administered to achieve therapeutic levels, then treatment efficacy is improved, but initial NPR-b activity increases causing hypotension
Solution Approach 1:
The controlled-release formulations deliver CNP agonist in a periodic or sustained manner over extended periods (half-life at least 6 hours), avoiding the sudden initial NPR-b activation that causes hypotension while maintaining therapeutic effects through prolonged lower-level stimulation
Solution Approach 2:
The invention uses controlled-release matrices, conjugates, or prodrug intermediaries that modulate the release and activation of CNP agonist, creating a buffer between administration and receptor activation that reduces initial NPR-b activity spikes while ensuring sustained therapeutic delivery
Data Source
AI summary
The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.